David Canner - 14 Feb 2025 Form 4 Insider Report for Inhibikase Therapeutics, Inc. (IKT)

Role
Director
Signature
/s/ Garth Lees-Rolfe, attorney-in-fact
Issuer symbol
IKT
Transactions as of
14 Feb 2025
Transactions value $
$0
Form type
4
Filing time
19 Feb 2025, 20:11:06 UTC
Previous filing
23 Oct 2024
Next filing
02 Jul 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IKT Stock Option (Right to Buy) Award $0 +22.6K $0.00 22.6K 14 Feb 2025 Common Stock 22.6K $2.35 Direct F1
transaction IKT Stock Option (Right to Buy) Award $0 +117K $0.00 117K 14 Feb 2025 Common Stock 117K $2.35 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The options vested and became exercisable on February 14, 2025.
F2 The options will vest and become exercisable in two equal annual installments on October 24, 2025 and October 24, 2026.